Application Note

BDNF Alternative (TrkB agonist) Peptide [ID: PG-003]
14days Stability in Cell Culture Medium at 37℃
Brain-derived neurotrophic factor (BDNF) binds to its counter receptor TrkB and increases
neuronal cell growth, neuronal survival and synaptic hyperfunction, as one of the essential
neurotrophic factors, and it is also confirmed to be expressed in the brain and periphery nerve[1]. BDNF plays an important role in maintaining nerve cell function, and its decrease has been
proposed to be associated with the onset of various neurological diseases including dementia,
suggesting its usefulness in the study to resolve these disease mechanisms [2, 3].
BDNF is currently used in several experiments to induce differentiation of various nerve cells
and to regulate their functions, but the previous report has already suggested that this protein
may be unstable in a physiological solution kept at 37°C, and that its half-life is detected to beapproximately several hours [4]. Therefore, for a long-time culture, the culture should be replacedwith fresh medium frequently depending on the used cells type and experimental conditions.
All the growth factor alternative peptides from PeptiGrowth have unique cyclic structure
understood to be structurally stable and are expected to be stable in the cell culture media [5].
At this testing, time-dependent changes of BDNF alternative peptide "PG-003" concentrations
in a liquid medium under standard cell culture conditions (at 37°C) were determined,demonstrating the PG-003 concentration was apparently maintained as over 80% evenafter 2 weeks (see below).

⚫

Method: PG-003 (final concentration: 100 nM) was added into the liquid medium (commerciallyavailable DMEM/F-12) and maintained at 37°C for 14 days. Relative concentrations of PG-003
were measured by LC/MS system at several points (at 0, 1, 3, 7, and 14 days).

⚫

Result: Concentrations were shown as maintained at 80% or higher even after 14 days undernormal cell culture conditions (N=3, mean ± SD, in the upper graph).
1

Application Note⚫

References：1) Binder DK & Scharfman HE. Growth Factors 2004; 22: 123-131.
2) Tapia-Arancibia L, et al. Brain Res Rev. 2008; 59: 201-220.
3) Brunoni AR, et al.

Int J Neuropsychopharmacol. 2008; 11: 1169-1180.

4) Bruggeman KF, et al. Nanoscale. 2017; 9: 13661-13669.
5) Nature Portfolio 2022. A growing market for synthetically produced peptides (nature.com)⚫

Precautions regarding the product：➢Please read the Safety Data Sheet (SDS) carefully prior to use the product.

➢

To use this product immediately after dissolving is recommended.

➢This product is a reagent for research use only. Not to use for any purpose other thanresearch or investigational use.

➢Specifications, contents, appearances, etc. of this product may be changed without notice.

➢Contact us or our sales agents, if with any large amounts or other special specification.

Product lineup
Product code

Factor Name

PG-001

HGF alternative peptide

PG-002

TGFβ1 inhibitor

PG-003

BDNF alternative peptide

PG-004

Noggin-like peptide

PG-005

BMP7 selective inhibitor

PG-006

BMP4 selective inhibitor

PG-007

VEGF alternative peptide

PG-008Wnt3a alternative peptide

PG-009Synthetic EGF (human)

PG-010

TPO alternative peptide《Contact regarding PeptiGrowth’s products and application notes》
Contact in North America

MIFI Bioceuticals

Contact in the EU/UK

IVICT Europe GmbH

Hackensack, NJ, USA

Duesseldorf, GERMANY

TEL: 201-242-5104

TEL: +49-(0)172-204-4403

E-mail: PG@mifibioceuticals.com

E-mail: koji.okada@ivic-t.com

PeptiGrowth Inc. Tokyo, JAPAN, TEL : +81-(0)70-4503-1497, E-mail : contact@peptigrowth.com

2